🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Acadia Healthcare Company, Inc. ACHC R3KPHARMA

Healthcare · Medical Care Facilities · United States
https://www.acadiahealthcare.com
Company Profile ↓
$27.50
+32.40% 1Y
Mkt Cap$2.56B
P/E-2.21
P/B1.29
52W High$35.61
52W Low$11.68
Book Value$21.78
EPS (TTM)$-12.42

Company Overview

Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company owns and operates acute inpatient psychiatric facilities; specialty treatment facilities comprising residential recovery facilities and eating disorder facilities; comprehensive treatment centers; and residential treatment centers, as well as facilities providing outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.

Recent Developments

  • Dec 2025 Revenue of $3.31B (+5.0% YoY); net profit $-1.10B.
  • Trailing 12 Months Year-on-year growth — revenue -0.4%, earnings -63.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 2.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:2.07%
1 Year:-0.40%

Compounded Profit Growth

5 Years:-
1 Year:-63.60%

Stock Price Performance

1 Year:+32.40%
6 Months:+11.29%
3 Months:+8.61%
1 Month:-12.78%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 66% of range
$11.68 $35.61
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)42.31 · Neutral
Price Performance
1M-12.78%
3M+8.61%
6M+11.29%
1Y+32.40%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-2.21
Industry PE
24.83
Forward P/E
15.09
PEG Ratio
1.37
Book Value
$21.78
Price to Book
1.29
P/S
0.78
EV/EBITDA
9.70
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
2.07%
Profit 5Y
-
Revenue (YoY)
-0.40%
Earnings (YoY)
-63.60%

Profitability & Returns

ROCE
7.76%
ROE
-41.45%
ROA
3.57%
Profit Margin
-33.44%
Op Margin
10.14%
Gross Margin
41.06%
EPS (Latest Qtr)
$0.12
EPS (TTM)
$-12.42

Balance Sheet & Liquidity

Debt/Equity
1.18
Quick Ratio
1.35
Current Ratio
1.57
Debt
$2.59B
Total Assets
$5.55B
Current Assets
$845.29M
Working Capital
$288.94M

Ownership

Promoter Holding
1.52%
Chg in Prom Hold
-
FII / Inst Holding
147.20%
Chg in FII Hold
-0.23%

Financial Snapshot

Enterprise Value
$2.56B
Total Revenue (TTM)
$3.37B
EBITDA
$534.85M
Free Cash Flow
$-104.96M
Operating Cash Flow
$210.52M
Shares Outstanding
93.10M
Gross Margin
41.06%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ACHC Acadia Healthcare Company, Inc. R3KPHARMA 27.50 -2.21 $2.56B 0.00% 7.76% -41.45% 2.07% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue --679.19M715.90M716.71M724.51M742.24M765.74M760.92M743.55M487.96M509.81M509.38M501.23M509.22M491.48M547.96M541.28M551.20M582.16M587.56M-616.65M651.72M666.73M-704.27M731.34M750.33M-768.05M796.04M815.63M-770.50M869.23M851.57M821.46M828.80M865.84M
Cost of Revenue -----------------------------------28.53M30.41M30.76M29.49M30.20M
Gross Profit -----------------------------------840.70M821.16M790.70M799.31M835.64M
Operating Expenses -----------------------------------698.40M701.64M743.05M715.48M747.87M
Operating Income 155.84M-136.37M162.22M152.26M-145.73M165.01M148.92M-136.00M158.89M146.64M-132.85M--------------------142.30M119.52M47.64M83.84M87.77M
EBITDA -----------------------------------134.14M124.07M-1.09B101.72M110.61M
Interest Expense -----------------------------------35.14M36.62M37.92M38.33M38.18M
Pretax Income -----------------------------------50.00M39.98M-1.17B10.96M22.01M
Tax Provision -----------------------------------12.07M1.67M7.84M6.50M9.75M
Net Income -117.81M41.82M34.96M49.63M45.62M69.63M50.82M58.84M46.23M-331.64M29.47M48.14M42.57M-11.25M33.46M41.08M37.00M-783.67M9.72M44.51M66.13M70.28M60.84M80.08M71.10M61.12M66.02M72.30M-217.71M57.73M76.38M78.48M68.13M32.62M8.37M30.13M36.25M-1.18B4.11M10.93M
Diluted EPS -1.360.480.400.570.520.800.580.670.53-3.800.340.550.48-0.130.380.460.42-8.780.110.490.73-0.670.880.78-0.720.79-2.39-0.830.850.74-0.090.330.40-13.020.050.12

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -------2.81B2.84B1.90B2.01B2.09B-2.61B2.93B3.15B3.31B
Cost of Revenue -------------100.20M105.99M112.71M118.05M
Gross Profit -------------2.51B2.82B3.04B3.19B
Operating Expenses -------------2.04B2.31B2.52B2.81B
Operating Income ---80.96M145.33M215.49M404.83M608.59M604.36M593.58M585.88M--467.69M513.01M522.28M387.96M
EBITDA -------------561.67M189.11M607.84M-737.83M
Interest Expense -------------69.76M82.12M116.37M138.86M
Pretax Income -------------374.14M-25.36M341.88M-1.07B
Tax Provision -------------94.11M-9.70M77.39M25.98M
Net Income 2.88M6.21M-34.89M20.40M42.58M83.04M112.55M6.14M199.84M-175.75M108.92M-672.13M-273.14M-21.67M255.61M-1.10B
Diluted EPS 0.160.35-1.860.530.851.501.640.072.30-2.011.24-7.59-2.98-0.242.78-12.16

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Nov 2011Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --45.40M-413.00M983.41M1.22B2.21B4.28B6.02B6.42B6.17B6.88B6.50B-4.99B5.36B5.96B5.53B
Current Assets ---------------506.12M596.00M577.49M814.14M
Cash & Equivalents 45.00K4.49M8.61M-61.12M49.40M4.57M94.04M11.21M57.06M67.29M50.51M99.53M378.70M-97.65M100.07M76.31M133.24M
Inventory ---------------5.09M5.30M5.65M5.69M
Receivables ---------------322.44M361.45M365.34M440.60M
Total Liabilities --20.29M-316.63M550.86M743.95M1.33B2.59B3.84B3.83B3.81B4.34B4.54B-2.09B2.47B2.77B3.39B
Current Liabilities --18.06M-40.67M71.85M114.69M165.93M290.20M342.87M377.39M416.38M463.58M1.31B-388.33M885.78M577.92M525.19M
Long Term Debt ---150.00M270.71M465.64M601.94M1.05B2.20B3.25B3.21B3.16B3.11B2.97B-1.36B1.34B1.88B2.47B
Total Debt ---------------1.53B1.50B2.09B2.64B
Total Equity --25.11M-96.36M432.55M480.71M880.97M1.68B2.17B2.57B2.33B2.51B1.90B-2.81B2.78B3.07B1.95B
Shares Outstanding ---------------89.91M91.26M91.78M90.45M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 6.17M8.20M-20.67M33.90M65.56M115.29M240.40M361.48M399.58M414.08M332.90M658.81M-380.57M462.34M129.69M131.90M
Investing Cash Flow -3.41M-1.50M-225.57M-524.64M-242.98M-860.77M--660.37M-336.53M-360.96M-201.14M-281.84M--305.83M-397.22M-736.48M-556.21M
Financing Cash Flow 1.69M-2.57M298.74M479.03M132.59M837.97M-358.84M-60.07M-67.33M-61.63M-51.50M--110.90M-62.70M583.02M481.25M
Capital Expenditure -334.00K-1.50M-9.56M-27.59M-68.94M-113.24M-276.05M-307.47M-274.18M-253.19M-232.68M-224.96M--296.15M-424.13M-690.38M-571.81M
Free Cash Flow 5.83M6.70M-30.22M6.30M-3.38M2.04M-35.64M54.01M125.40M160.89M100.22M433.84M-84.42M38.21M-560.69M-439.91M
Net Change in Cash --------------36.16M2.42M-23.77M56.94M
Share Buybacks ----------------50.03M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------96.2%96.4%96.4%96.4%
Operating Margin % -------21.7%21.3%31.2%29.2%--17.9%17.5%16.6%11.7%
Net Margin % -------0.2%7.0%-9.2%5.4%-32.2%-10.5%-0.7%8.1%-33.3%
ROE % -24.7%-36.2%4.7%8.9%9.4%6.7%0.3%7.8%-7.5%4.3%-35.4%-9.7%-0.8%8.3%-56.6%
ROCE % ---8.9%13.1%10.6%10.1%10.7%10.0%10.3%9.1%--10.2%11.5%9.7%7.8%

Shareholding Pattern

Insiders
1.52%
Institutions
147.20%
Public Float
149.48%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 16.07% 14.96M $423.74M
2 Wellington Management Group, LLP 6.15% 5.73M $162.22M
3 Vanguard Portfolio Management LLC 5.77% 5.37M $152.12M
4 FMR, LLC 5.39% 5.02M $142.10M
5 Carronade Capital Management, Lp 5.12% 4.76M $134.93M
6 Morgan Stanley 4.87% 4.53M $128.46M
7 Deerfield Management Company, L.P 4.85% 4.52M $128.05M
8 DME Capital Management, LP 4.73% 4.40M $124.67M
9 Farallon Capital Management LLC 4.53% 4.22M $119.58M
10 Abrams Bison Investments, LLC 4.47% 4.17M $117.99M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ACHC

Yahoo Finance hu, 27 Aug 2026

Acadia Healthcare (ACHC) Up 11.8% Since Last Earnings Report: Can It Continue?

Acadia Healthcare (ACHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo Finance Fri, 14 Aug 2026

2 Small-Cap Stocks on Our Watchlist and 1 We Turn Down

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to t…

Yahoo Finance hu, 30 Jul 2026

Acadia Healthcare's Operational Turnaround Progressing as New Facilities Open on Schedule, UBS Says

Acadia Healthcare's (ACHC) operational turnaround is advancing, with new facilities opening on sched

Yahoo Finance hu, 30 Jul 2026

Acadia Healthcare (ACHC) Stock May Be A Bargain On Sales Yet Fully Priced On Expectations

Acadia Healthcare Company has had a strong year so far, with the share price up 91.4% year to date, while the valuation checks still suggest the stock leans cheap on most measures. The 91.4% year to date gain raises the question of whether …

Yahoo Finance hu, 30 Jul 2026

Why Acadia Healthcare (ACHC) Shares Are Getting Obliterated Today

Shares of behavioral health company Acadia Healthcare (NASDAQ:ACHC) fell 13.3% in the afternoon session after the company reported mixed second-quarter results that overshadowed beats on headline numbers.…

Yahoo Finance Wed, 29 Jul 2026

Acadia Healthcare Co Inc (ACHC) Q2 2026 Earnings Call Highlights: Strong Financial Management ...

Acadia Healthcare Co Inc (ACHC) surpasses revenue guidance and reduces debt, while facing flat revenue growth and increased liability reserves.

ACHC — Frequently Asked Questions

What is the current share price of Acadia Healthcare Company, Inc. (ACHC)?

As of 2026-09-19 21:16 PDT, Acadia Healthcare Company, Inc. (ACHC) trades at $27.50 on NasdaqGS. Its 52-week range is $11.68 to $35.61.

What is the market capitalisation of ACHC?

Acadia Healthcare Company, Inc. (ACHC) has a market capitalisation of $2.56B on NasdaqGS.

What is the P/E ratio of ACHC?

ACHC trades at a trailing price-to-earnings (P/E) ratio of -2.21. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.29.

What is the return on equity (ROE) of ACHC?

ACHC has a return on equity (ROE) of -41.45%. Its return on capital employed (ROCE) is 7.76%.

Is ACHC a good stock to buy?

This page provides a data-driven analysis of Acadia Healthcare Company, Inc. (ACHC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space